Results 41 to 50 of about 2,262 (198)

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

, 2015
BACKGROUND & AIMS: Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this ...
BRUNETTO, MAURIZIA ROSSANA, Everson, G, Kugelmas, M, Pol, S, Jensen, D., Vierling, J, Zeuzem, S, Serfaty, L, de Ledinghen, V, Elkhashab, M, Younes, Zh, Hézode, C, Hennicken, D, Bernstein, D, Sherman, Ke, Luketic, V, Mauss, S, Heo, J, Mcphee, F, Tran, A   +19 more
core   +2 more sources

Asunaprevir-containing regimens for the treatment of hepatitis C virus infection

, 2017
Chronic hepatitis C virus (HCV) infection has been a tremendous health burden worldwide with an annual mortality of 300,000 people due to decompensated cirrhosis or hepatocellular carcinoma.
Yang, Sheng-Shun;Kao, Jia-Horng, 高嘉宏   +1 more
core   +1 more source

Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V

Журнал инфектологии, 2020
The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development  of mixed  type  III  cryoglobulinemia,  cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic ...
N. V. Dunaeva, M. A. Chirskaya, E. Yu. Kolpashchikova, S. Yu. Romanova, S. V. Lapin, V. E. Karev, D. A. Gusev   +6 more
doaj   +1 more source

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis [PDF]

, 2015
IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. OBJECTIVE: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor),
Everson, G, Muir, Andrew J., McPhee, Fiona, Poordad, Fred, Dore, Gregory J, Yin, Philip D., Ramji, A, Yang, R, Ghesquiere, W, Pockros, Paul J, Hughes, Eric A., Reau, N, Thompson, AJ, Pockros, Paul J., Swenson, E. Scott, Pockros, PJ, Kwo, P, Ghesquiere, Wayne, Vierling, J, Tran, Albert, Reau, Nancy, Muir, Andrew J, Yang, Rong, Everson, Gregory, Tran, A, Lalezari, Jacob, Thompson, Alexander J, Herring, R, Lalezari, J, Hézode, Christophe, Vierling, John, Yozviak, J, Ramji, Alnoor, Yozviak, Joseph, Freilich, B, Sheikh, A, Cooper, James, Hézode, C, Stuart, K, Poordad, F, Hughes, EA, Dore, Gregory J., Swenson, ES, Swenson, E Scott, Freilich, Bradley, Yin, Philip D, Sheikh, Aasim, Muir, AJ, Kwo, Paul, Yozviak, Joseph L, DO, FACP, Hughes, Eric A, McPhee, F, Thompson, Alexander J., Dore, GJ ; https://orcid.org/, Herring, Robert, Stuart, Katherine, Yin, PD, Cooper, J   +57 more
core   +2 more sources

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in ...
V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina   +13 more
doaj   +1 more source

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. [PDF]

PLoS Computational Biology, 2015
Recent discoveries of direct acting antivirals against Hepatitis C virus (HCV) have raised hopes of effective treatment via combination therapies.
Ruian Ke, Claude Loverdo, Hangfei Qi, Ren Sun, James O Lloyd-Smith   +4 more
doaj   +1 more source

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

, 2014
International audienceBackground & AimsAsunaprevir is a selective HCV NS3 protease inhibitor, active against genotypes 1, 4, 5, and 6 in vitro. We evaluated asunaprevir plus peginterferon alfa-2a/ribavirin (PegIFNα/RBV) for genotype 1 and 4 chronic HCV ...
Cohen, David, Hughes, Eric, Ratziu, Vlad, Bessone, Fernando, Mendez, Patricia, Younes, Ziad, Bronowicki, Jean-Pierre, Thuluvath, Paul, Martorell, Claudia, Terg, Ruben, He, Bing, Pol, Stanislas, Hernandez, Dennis, Mcphee, Fiona, Eley, Timothy, Yu, Fei, Gadano, Adrian   +16 more
core   +1 more source

Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches

Advances in Virology, 2015
Current combination therapy of PEG-INF and ribavirin against the Hepatitis C Virus (HCV) genotype-1 infections is ineffective in maintaining sustained viral response in 50% of the infection cases.
Vivek Chandramohan, Anubhav Kaphle, Mamatha Chekuri, Sindhu Gangarudraiah, Gowrishankar Bychapur Siddaiah   +4 more
doaj   +1 more source

Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection

BMC Bioinformatics, 2017
Background Viruses of the flaviviridae family are responsible for some of the major infectious viral diseases around the world and there is an urgent need for drug development for these diseases.
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu, Jinn-Moon Yang   +5 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source